In our study, the loss of CLDN3 expression observed in CRPC cells and tumors could be explained, at least in part, by the loss of CLDN3 control by AR, since it has been demonstrated that AR regulates a different expression profile in androgen-sensitive and independent prostate cancer cells. The gene discussed is AR; the disease is prostate carcinoma.